预约演示
更新于：2026-03-10
Voriconazole
伏立康唑
更新于：2026-03-10
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H14F3N5O |
InChIKeyBCEHBSKCWLPMDN-MGPLVRAMSA-N |
CAS号137234-62-9 |
关联
269
项与 伏立康唑 相关的临床试验NCT07426042
A Clinical Study Evaluating the Effects of Dexamethasone on the Activities of CYP2C9, CYP2C19, and CYP3A4 Substrates in Healthy Male Subjects
Purpose:
The purpose of this study is to understand how dexamethasone affects the activity of drug-metabolizing enzymes in the body and how this may influence interactions with other medicines, such as voriconazole.
Background:
Many medicines are broken down in the body by enzymes called cytochrome P450 (CYP) enzymes. Differences in CYP enzyme activity between individuals can lead to variability in drug response and drug-drug interactions. Dexamethasone is known to affect CYP enzyme activity, and voriconazole is a medication that is metabolized by these enzymes.
Participants:
This study will include a total of 12 healthy adult male volunteers. Participants will be grouped based on their metabolic status, including 6 normal metabolizers (NM) and 6 poor metabolizers (PM).
Interventions:
Participants will receive a combination of probe drugs known as a CYP probe cocktail to assess baseline CYP enzyme activity. Dexamethasone will be administered, and the CYP probe cocktail will be given again to evaluate changes in enzyme activity. Voriconazole will be used to assess the potential for drug-drug interactions related to changes in CYP enzyme activity. Blood samples will be collected during the study.
Outcome Measures:
The main outcomes of this study are changes in blood concentrations of the probe drugs, which reflect changes in CYP enzyme activity, and comparisons of these changes between normal metabolizers and poor metabolizers.
Hypothesis:
The study hypothesizes that dexamethasone alters CYP enzyme activity and that the magnitude of this effect differs between normal metabolizers and poor metabolizers, potentially affecting the metabolism of drugs such as voriconazole.
The purpose of this study is to understand how dexamethasone affects the activity of drug-metabolizing enzymes in the body and how this may influence interactions with other medicines, such as voriconazole.
Background:
Many medicines are broken down in the body by enzymes called cytochrome P450 (CYP) enzymes. Differences in CYP enzyme activity between individuals can lead to variability in drug response and drug-drug interactions. Dexamethasone is known to affect CYP enzyme activity, and voriconazole is a medication that is metabolized by these enzymes.
Participants:
This study will include a total of 12 healthy adult male volunteers. Participants will be grouped based on their metabolic status, including 6 normal metabolizers (NM) and 6 poor metabolizers (PM).
Interventions:
Participants will receive a combination of probe drugs known as a CYP probe cocktail to assess baseline CYP enzyme activity. Dexamethasone will be administered, and the CYP probe cocktail will be given again to evaluate changes in enzyme activity. Voriconazole will be used to assess the potential for drug-drug interactions related to changes in CYP enzyme activity. Blood samples will be collected during the study.
Outcome Measures:
The main outcomes of this study are changes in blood concentrations of the probe drugs, which reflect changes in CYP enzyme activity, and comparisons of these changes between normal metabolizers and poor metabolizers.
Hypothesis:
The study hypothesizes that dexamethasone alters CYP enzyme activity and that the magnitude of this effect differs between normal metabolizers and poor metabolizers, potentially affecting the metabolism of drugs such as voriconazole.
开始日期2026-04-01 |
申办/合作机构- |
NCT07457203
Clinical Study on the Drug Interaction Between Buagafuran Capsules and Voriconazole Tablets in Chinese Adult Healthy Participants
This study is a non-randomized, open label trial aimed at evaluating the drug interaction between Buagafuran capsules and voriconazole tablets in Chinese adult healthy participants.The research period is 7 days in total.
开始日期2026-04-01 |
申办/合作机构 |
ChiCTR2500104674
Evaluation of the efficacy and safety of nebulized inhalation of amphotericin B deoxycholate (AmB-D) combined with azole in the treatment of invasive pulmonary mycosis in patients with hematological malignancies: A multicenter, prospective, randomized controlled study
开始日期2025-06-13 |
申办/合作机构- |
100 项与 伏立康唑 相关的临床结果
登录后查看更多信息
100 项与 伏立康唑 相关的转化医学
登录后查看更多信息
100 项与 伏立康唑 相关的专利（医药）
登录后查看更多信息
8,441
项与 伏立康唑 相关的文献（医药）2026-12-31·ANNALS OF MEDICINE
The association between different regimens of glucocorticoid and antifungal treatment with the prognosis of allergic bronchopulmonary aspergillosis: a retrospective cohort study
Article
作者: Chen, Lei ; Wang, Qin ; Jiang, Hongni ; Xu, Yiding ; Wang, Minghui ; Wang, Sijiao ; Li, Huayin ; Zhu, Xiaodan ; Zhang, Xiaohua
BACKGROUND:
Optimal management of allergic bronchopulmonary aspergillosis (ABPA) remains debated, particularly regarding glucocorticoid (GC) dosage, duration, antifungal selection, and combination therapy. This study evaluated the impact of different regimens on ABPA prognosis.
METHODS:
A total of 76 ABPA patients at Zhongshan Hospital, Fudan University from March 2009 to June 2018 were enrolled and stratified by one-year relapse status. Demographics, treatment details (GC dosage, GC duration, antifungal type), and outcomes (GC dependence, acute exacerbations, lesion resolution, recurrence) were analyzed. Multivariate logistic regression analysis was utilized.
RESULTS:
No significant difference were observed between the relapse group (n = 20) and non-relapse group (n = 56) in baseline demographics, clinical characteristics, or use of GC duration/dosage or antifungals. The mean follow-up time for the relapse and non-relapse groups were 23.95 vs 24.91 months. The former had higher long-term GC use (>3 months) than the non-relapse group (80% vs. 30.36%, p < 0.001). Long-term GC was an independent risk factor for relapse (OR 6.85, 95%CI 1.51-31.51), GC dependence (OR 5.92, 95%CI 1.29-27.11), and acute exacerbations (OR 9.41, 95%CI 2.76-32.06). Conversely, low-dose GC (<7.5 mg/day) reduced relapse risk (OR 0.06, 95%CI 0.01-0.36), GC dependence (OR 0.07, 95%CI 0.01-0.41), and exacerbations (OR 0.16, 95%CI 0.03-0.91). Voriconazole offered superior initial efficacy vs itraconazole (OR 4.42, 95%CI 1.18-16.52) but poorer long-term lesion resolution (OR 0.24, 95%CI 0.06-0.97). Nevertheless, a higher proportion of non-relapse patients had received combination therapy compared to relapse patients (67.9% vs. 50%, p = 0.322).
CONCLUSION:
Long-term GC increases risks of adverse outcomes in ABPA, while low-dose GC demonstrates protective effects. Voriconazole provides better initial response but inferior long-term lesion resolution compared to itraconazole. More non-relapse patients on combination therapy may related to possible benefit of combination therapy. Prospective studies are warranted to confirm these findings.
2026-12-31·Journal of Pharmaceutical Policy and Practice
Comparative pharmacokinetics of voriconazole between elderly and young adult patients: a population pharmacokinetic study
Article
作者: Sattar, Adeel ; Zulfiqar, Sadaf ; Akbar, Zunaira ; Zaryab Zakria, Khawaja ; Ali, Mohsin ; Zahid Mushtaq, Muhammad ; Usman, Muhammad ; Rasheed, Huma ; Alvi, Ijaz ; Hussain, Talib ; Rehan Khan, Muhammad ; Bilal, Hajira
Background:
Voriconazole (VCZ) belongs to the class of broad-spectrum antifungal agents, and it is commonly used for the treatment of serious fungal infections. Safe and effective therapy with VCZ is a challenge due to the narrow therapeutic index and high variability in pharmacokinetics between patients. Age of the patients can be a significant factor for this variability. However, no prior study in Pakistan has compared the pharmacokinetics of VCZ among young and elderly patients.
Methods:
A population pharmacokinetic model was developed on NONMEM software by using therapeutic drug monitoring (TDM) data from 51 cancer patients. Patients were divided into two age groups, that is ≤ 65 years and > 65 years. The covariate influence on CL of VCZ was assessed by stepwise covariate modelling. The predictive performance and stability of the final model were evaluated by using goodness-of-fit plots and bootstrap analysis, respectively.
Results:
A one-compartment model with first-order elimination best described the data. The CL of VCZ in patients with age > 65 years was 3.11 L/h, which was significantly lower than the CL in patients with age ≤ 65 years, which was 6.46 L/h. No other covariate proved significant on CL and volume of distribution of VCZ. The final model demonstrated robust predictive performance and stability.
Conclusions:
The reduced CL of VCZ in elderly patients might be due to compromised hepatic enzymes in elderly patients. The dose of VCZ should be reduced in patients aged > 65 years.
2026-12-01·PARASITOLOGY RESEARCH
Multidrug-resistant Acanthamoeba keratitis caused by the T4 Genotype: A case report
Article
作者: Kazemirad, Elham ; Atighehchian, Mehrnaz ; Zarei-Ghanavati, Mehran ; Kasiri, Maryam ; Latifi, Alireza
This report describes the case of a 28-year-old woman, who presented with a two-week history of severe ocular pain and photophobia in her right eye. She was a soft contact lens wearer with no history of ocular trauma or systemic illness. Ophthalmic examination revealed conjunctival hyperemia, epithelial irregularities, and a developing ring-shaped stromal infiltrate. In vivo confocal microscopy demonstrated double-walled hyperreflective cysts, and culture followed by PCR and sequencing confirmed the presence of Acanthamoeba T4 genotype. Despite intensive treatment with topical polyhexamethylene biguanide, chlorhexidine, propamidine, and voriconazole, as well as oral miltefosine, the infection progressed, leading to stromal necrosis. The patient underwent two therapeutic penetrating keratoplasties; however, the disease continued to advance, eventually resulting in phthisis bulbi and permanent vision loss. This case highlights the potential for aggressive, clinically refractory Acanthamoeba keratitis caused by the T4 genotype, emphasizing the importance of early diagnosis, vigilant monitoring, and timely surgical intervention in resistant cases.
612
项与 伏立康唑 相关的新闻（医药）2026-03-09
作者：苏欣 孙超
第一作者单位：南京大学医学院附属鼓楼医院呼吸与危重症医学科
通信作者：苏欣，南京大学医学院附属鼓楼医院呼吸与危重症医学科
引用本文: 苏欣, 孙超. 侵袭性肺曲霉病的药物治疗新进展与展望[J]. 中华结核和呼吸杂志, 2026, 49(2): 109-112. DOI: 10.3760/cma.j.cn112147-20250804-00466.
摘要
本文介绍了侵袭性肺曲霉病（IPA）治疗的最新进展，包括新型抗真菌药物、给药途径优化及未来治疗策略。新型抗真菌药物如艾沙康唑、泊沙康唑新剂型、两性霉素B脂质体、瑞扎芬净和艾瑞芬净等，在药代动力学、药效学和安全性方面各有特点。纳米递送系统和吸入制剂提高了药物在气道部位的浓度，同时减少了全身不良反应。未来将针对真菌蛋白新靶点、多靶点开展新药研发以及免疫调节治疗等。
侵袭性肺曲霉病（invasive pulmonary aspergillosis，IPA）是一种严重威胁生命的真菌感染，全球发病率和临床疾病负担被严重低估［1］。早期诊断、及时启动恰当的抗曲霉治疗对提高患者生存率至关重要。临床常用抗曲霉感染药物包括三唑类、多烯类和棘白菌素类等，现有药物尚不能满足临床需求。合理选择治疗药物及治疗方式需要依据抗曲霉药物的药代动力学和药效学特点、治疗药物监测（therapeutic drug monitoring，TDM）、药物间相互作用（drug-drug interaction，DDI）和药物不良反应等。近年来不断有新型抗曲霉药物获批上市，一些具有新作用机制的抗真菌药物也在研发中。
一、IPA的治疗新进展
《侵袭性肺真菌病诊治指南（2025年版）》针对IPA的治疗药物提出了明确的建议。近20年来，伏立康唑一直是治疗IPA的一线方案，但其血药浓度受多种因素影响，在中国人群中存在较大差异。此外，伏立康唑是CYP3A4等肝酶的强抑制剂，与多种药物存在显著的DDI。因此，指南强调使用伏立康唑时应特别注意进行TDM管理，以优化给药剂量，在保证疗效的同时减少不良反应［2］。除伏立康唑外，新指南也纳入了近年来新进入临床的抗真菌药物，这些新型药物在安全性和使用便捷性等方面获得了改进（表1）。
1. 艾沙康唑：肺组织浓度高，个体间血药浓度变异性低，药代动力学稳定，可静脉序贯口服给药。与其他三唑类药物相比，艾沙康唑对CYP3A4抑制作用较低，DDI较少［2］。基于良好的疗效和安全性等临床特性，艾沙康唑已被多项指南推荐作为治疗IPA的一线选择。
2. 泊沙康唑：长侧链结构增强对CYP51亲和力，降低耐药风险。药物在肺组织浓度远高于血浆，有利于肺部感染的治疗。治疗IPA疗效不逊于伏立康唑，且42 d全因病死率更低。难治或耐药感染可加量并监测血药浓度。治疗药物浓度监测建议为谷浓度≥1 mg/L，预防时建议为≥0.5 mg/L。
3. 两性霉素B脂质体（Liposomal Amphotericin B，L-AmB）：在IPA的目标治疗中，若伏立康唑等唑类药物疗效不佳或发生耐药，可选用L-AmB单药治疗或含L-AmB的双药联合治疗。在三唑类耐药率超过10%的医疗单位，或者不能排除合并毛霉感染的IPA中，可将L-AmB作为一线治疗方案的选择。
4. Fosmanogepix：是一种水溶性磷酸盐前体药物，通过碱性磷酸酶代谢为活性形式 Manogepix。该药通过靶向抑制真菌糖基磷脂酰肌醇（GPI）锚定蛋白转移1（Gwt1）基因，破坏真菌细胞壁的完整性，进而导致细胞死亡。该药可覆盖多种酵母菌和霉菌，且在体内组织分布广泛，口服生物利用度超过90%，能够方便地实现静脉给药与口服给药的序贯治疗。此外，Fosmanogepix的DDI较少，这使其在临床使用过程中更加便捷。目前，Fosmanogepix已获得美国食品药品监督管理局（FDA）授予的“快速通道”资格和“孤儿药”认定，用于治疗包括IPA在内的多种侵袭性真菌病。欧洲药品管理局（EMA）也将该药确定为治疗IPA的“孤儿药”［3］。
5. Olorofim（F901318）：一种新型抗真菌药物，通过抑制真菌的二氢乳清酸脱氢酶（DHODH）活性发挥作用，但对人DHODH无活性，因此安全性良好。体外数据提示，Olorofim对唑类耐药曲霉表现出较高活性。Olorofim已被FDA和EMA授予孤儿药资格、合格传染病产品资格认定或突破性疗法认定，用于治疗IPA等侵袭性真菌感染［4］。
6. 瑞扎芬净：是一种新型棘白菌素类药物，通过抑制 β-（1，3）-D-葡聚糖合成酶有效地抑制曲霉活性，半衰期长达133 h，一周仅需给药一次，极大地提升了患者用药便捷性和依从性［5］。体外数据显示，瑞扎芬净对曲霉具有抗菌活性，但尚需要进一步临床研究以支持其在治疗IPA患者中的应用［6］。
7. 艾瑞芬净：Scynexis公司开发的三萜类抗真菌药物，是一种结构独特的新型β-（1，3）-D-葡聚糖合成酶抑制剂。其作用机制与棘白菌素类药物类似，通过抑制1.3-β-D-葡聚糖的合成靶向作用于真菌细胞壁，从而达到破坏真菌的目的。与棘白菌素类药物相比，该药具有较高的口服生物利用度。体外数据显示，艾瑞芬净与唑类或两性霉素B联合对曲霉表现出显著协同作用，其在IPA的联合治疗方面具有一定的应用前景［5］。
二、IPA治疗药物给药新途径
除已经上市或即将进入临床的新型药物外，改变原有给药途径也是提高疗效与安全性的重要措施。
1. 纳米递送系统：在提高抗真菌药物的疗效和安全性方面发挥了重要作用。纳米技术能够改善药物的溶解性、稳定性和靶向性，从而提高药物在感染部位的浓度，减少全身毒性反应。（1）脂质体纳米粒：是目前应用最广泛的纳米递送系统之一。其通过将药物包裹在脂质双层中，能够显著提高药物的稳定性和生物利用度。例如，L-AmB在 IPA 治疗中表现出良好的疗效和安全性。（2）聚合物纳米粒：具有良好的生物相容性和可降解性。通过设计特定的聚合物材料，可以实现药物的缓释和靶向递送。
2. 吸入制剂：吸入制剂通过将药物直接输送到肺部感染部位，能够显著提高药物的局部浓度，减少全身毒性反应。两性霉素 B 雾化吸入是目前研究较多的吸入制剂之一。研究表明，雾化吸入两性霉素 B 能够在肺部形成高浓度的药物环境，有效抑制曲霉的生长，同时减少全身毒性反应［5］。然而，目前临床数据仍较为有限，需要进一步研究其在不同临床场景中的应用效果。
三、IPA治疗新方法展望
1. 针对真菌蛋白的潜在治疗靶点：（1）CotA激酶：该酶通过保守的下游效应物和翻译抑制因子SsdA部分发挥调控作用，从而驱动烟曲霉的侵袭性生长和毒力表达。CotA激酶的研究为开发新的抗真菌策略提供了潜在靶点［7］。未来的研究方向包括进一步研究CotA激酶的结构和功能，开发特异性抑制剂。（2）特异性蛋白Ntp1：Ntp1的417-588氨基酸区域是抗真菌蛋白（AFPs）结合的关键位点，且在调节真菌生长、发育、孢子形成、菌核形成、毒素合成和致病性方面发挥重要作用，为开发新型抗真菌药物和策略提供了重要的分子靶点［8］。然而，Ntp1在不同真菌中的保守性和功能多样性尚需进一步研究，这可能影响药物的广谱活性。
2. 研发针对多靶点药物，应对多重耐药真菌感染：多靶点药物的研发是应对多重耐药真菌感染的重要策略。（1）聚噁唑啉活性分子：我国研究者通过以聚噁唑啉的非天然骨架多肽结构模拟宿主防御肽、同时引入DNA结合功能基团，成功设计了细胞膜和DNA双靶点抗耐药真菌聚噁唑啉活性分子。双靶点活性分子对多种临床常见耐药真菌（包括烟曲霉）具有高杀菌活性和选择性，展现出良好的临床应用前景［9］。（2）Mandimycin：Mandimycin是一种含有Mycosamine和罕见二脱氧糖基团的多烯大环内酯类抗生素。该药通过特异性的靶向结合真菌细胞膜中多种磷脂（如磷脂酰肌醇、磷脂酰乙醇胺等），破坏细胞膜完整性，导致细胞内离子泄漏和细胞死亡。其独特的化学结构同时保证了更好的药代动力学特性和更低的肾毒性，为开发新的抗真菌疗法提供了新方向［10］。
3. 免疫调节协助抗真菌治疗：治疗IPA、改善患者预后除了早期有效抗真菌药物的应用，同时还需关注改善患者免疫状态。其中“宿主导向治疗（host-directed therapy，HDT）”是未来的重要治疗突破方向。HDT通过调节宿主的免疫反应，增强机体对真菌的防御能力，从而与抗真菌药物协同作用，提高治疗效果。目前已探索到多种与IPA相关的潜在免疫治疗靶点，包括自噬关键蛋白ATG16L1［11］，B细胞受体信号通路的关键分子BTK，C型凝集素受体Dectin-1［12］以及长链正五聚素蛋白3（PTX3）［13］。这些靶点的作用机制见表2。
非中性粒细胞减少型IPA患者，虽无明显中性粒细胞减少，但可能因慢性肺部疾病、免疫抑制剂使用、糖尿病等存在其他免疫功能缺陷，导致抗曲霉免疫防御能力下降。HDT可针对这些患者的特定免疫缺陷进行调节，增强抗真菌免疫反应，提高治疗效果。部分针对上述免疫调节分子的抗体或小分子处于临床试验阶段。例如，针对BTK的抑制剂，虽主要用于血液系统恶性肿瘤，但其调节免疫反应的潜力也受关注，未来可以探索其在抗真菌免疫调节中的应用。
四、总结
近年来新型抗真菌药物研发取得了一些进展，但仍面临诸多挑战。未来，抗真菌药物的研发和抗真菌治疗有可能在多个方面取得突破。深入研究真菌病原体的致病机制和宿主免疫反应，为新药研发和新方案提供更多靶点与思路。积极推进新型药物递送技术的研究，也是提高疗效与安全性的新方法。最后，我们可以通过精准诊疗研究（如诊疗模型指导下早期精准诊断和用药剂量精准预测等）［14］，进一步优化抗真菌药物的应用，实现疗效与安全性的提升。
参考文献（略）
点击页面左下角“阅读原文”，加入读者俱乐部下载全文
2026-03-08
·信狐药迅
每周药品注册获批数据，分门别类呈现，一目了然。(3.2-3.8）
新药上市申请
药品名称
企业
注册分类
受理号
硫酸索美来昔片
浙江杭煜制药有限公司
1
CXHS2500061
吡洛西利片
轩竹生物科技股份有限公司
1
CXHS2500051
TQ05105片
正大天晴药业集团股份有限公司
1
CXHS2400053
伊诺格鲁肽注射液
杭州先为达生物科技股份有限公司
1
CXSS2400141
伊诺格鲁肽注射液
杭州先为达生物科技股份有限公司
1
CXSS2400140
新药临床申请
药品名称
企业
注册分类
受理号
TQB3205胶囊
正大天晴药业集团股份有限公司
1
CXHL2600125
TQB3205胶囊
正大天晴药业集团股份有限公司
1
CXHL2600124
ETD-001凝胶
无锡奕拓医药科技有限责任公司
1
CXHL2600107
ETD-001凝胶
无锡奕拓医药科技有限责任公司
1
CXHL2600106
ETD-001凝胶
无锡奕拓医药科技有限责任公司
1
CXHL2600105
GLR2037片
甘李药业股份有限公司
1
CXHL2600099
GLR2037片
甘李药业股份有限公司
1
CXHL2600098
WGI-0301
浙江海昶生物医药股份有限公司
1
CXHL2600103
注射用TRD221
中国医学科学院药物研究所
1
CXHL2501483
HSK50042片
上海海思盛诺医药科技有限公司
1
CXHL2501482
HSK50042片
上海海思盛诺医药科技有限公司
1
CXHL2501481
ENC0653软膏
轶诺(浙江)药业有限公司
1
CXHL2501457
ENC0653软膏
轶诺(浙江)药业有限公司
1
CXHL2501456
ENC0653软膏
轶诺(浙江)药业有限公司
1
CXHL2501455
ENC0653软膏
轶诺(浙江)药业有限公司
1
CXHL2501454
ENC0653软膏
轶诺(浙江)药业有限公司
1
CXHL2501453
SIM0532片
上海先纬医药科技有限公司
1
CXHL2501463
SIM0532片
上海先纬医药科技有限公司
1
CXHL2501462
HLX97片
上海复宏瑞霖生物技术有限公司
1
CXHL2501459
HLX97片
上海复宏瑞霖生物技术有限公司
1
CXHL2501458
注射用FZ-P001钠
上海复旦张江生物医药股份有限公司
1
CXHL2501449
CMS-D008注射液
深圳市康哲生物科技有限公司
1
CXHL2501446
KC1036片
北京康辰药业股份有限公司
1
CXHL2501431
KC1036片
北京康辰药业股份有限公司
1
CXHL2501430
RX608片
苏州润新生物科技有限公司
1
CXHL2501445
RX608片
苏州润新生物科技有限公司
1
CXHL2501444
D3S-002片
德昇济医药(无锡)有限公司
1
CXHL2501440
D3S-002片
德昇济医药(无锡)有限公司
1
CXHL2501439
D3S-002片
德昇济医药(无锡)有限公司
1
CXHL2501438
D3S-002片
德昇济医药(无锡)有限公司
1
CXHL2501436
D3S-001胶囊
德昇济医药(无锡)有限公司
1
CXHL2501435
INT-210胶囊
宜坤行健生物医药(上海)有限公司
1
CXHL2501433
INT-210胶囊
宜坤行健生物医药(上海)有限公司
1
CXHL2501432
RGT-274-CR胶囊
上海齐鲁锐格医药研发有限公司
1
CXHL2501419
RGT-274-CR胶囊
上海齐鲁锐格医药研发有限公司
1
CXHL2501418
RGT-274-CR胶囊
上海齐鲁锐格医药研发有限公司
1
CXHL2501417
AZD9750
阿斯利康全球研发(中国)有限公司
1
CXHL2501416
AZD9750
阿斯利康全球研发(中国)有限公司
1
CXHL2501415
AZD9750
阿斯利康全球研发(中国)有限公司
1
CXHL2501414
INT-210胶囊
宜坤行健生物医药(上海)有限公司
1
CXHL2501428
INT-210胶囊
宜坤行健生物医药(上海)有限公司
1
CXHL2501427
RP-0172胶囊
砺博(深圳)生物科技有限公司
1
CXHL2501406
RP-0172胶囊
砺博(深圳)生物科技有限公司
1
CXHL2501405
RP-0172胶囊
砺博(深圳)生物科技有限公司
1
CXHL2501404
注射用PTT-936
北京炎明生物科技有限公司
1
CXHL2501413
MDI-1228_mesylate滴眼液
迈英诺医药科技(珠海)有限公司
1
CXHL2501402
MDI-1228_mesylate滴眼液
迈英诺医药科技(珠海)有限公司
1
CXHL2501401
注射用替曲朵辛
厦门朝阳生物工程有限公司
1
CXHL2501340
GSBR-5746片
上海硕迪生物技术有限公司
1
CXHL2501332
GSBR-5746片
上海硕迪生物技术有限公司
1
CXHL2501331
GSBR-5746片
上海硕迪生物技术有限公司
1
CXHL2501330
GSBR-5746片
上海硕迪生物技术有限公司
1
CXHL2501329
BTP4327
江苏诺和必拓新药研发有限公司
2.3
CXHL2501425
盐酸伊立替康脂质体注射液(II)
上海恒瑞医药有限公司
2.4
CXHL2501469
去氧胆酸注射液
南京迈诺威医药科技有限公司
2.4
CXHL2501393
发热伴血小板减少综合征灭活疫苗(Vero细胞)
国药中生生物技术研究院有限公司
1.1
CXSL2501069
BG-A3004注射液
广州百济神州生物制药有限公司
1
CXSL2600146
EA5注射液皮下制剂
山东览屹医药科技有限公司
1
CXSL2600126
BG-A3004注射液
广州百济神州生物制药有限公司
1
CXSL2600129
ONC-841注射液
北京昂科免疫科技有限公司
1
CXSL2600115
VG801
德康明基医疗科技(上海)有限公司
1
CXSL2600074
JSKN033注射液
江苏康宁杰瑞生物制药有限公司
1
CXSL2501135
注射用SG1827
杭州尚健生物技术股份有限公司
1
CXSL2501133
注射用BG-C477
广州百济神州生物制药有限公司
1
CXSL2501131
HLX3901注射液
上海复宏瑞霖生物技术有限公司
1
CXSL2501130
注射用BAT8008
百奥泰生物制药股份有限公司
1
CXSL2501127
SHR-3836注射液
上海恒瑞医药有限公司
1
CXSL2501118
SHR-3836注射液
上海恒瑞医药有限公司
1
CXSL2501117
TQB6457注射液
上海正大天晴医药科技开发有限公司
1
CXSL2501122
注射用BL-B01D1
成都百利多特生物药业有限责任公司
1
CXSL2501111
GK01活菌散
浙江迈亚塔菌检智能科技有限公司
1
CXSL2501110
注射用BL-B01D1
成都百利多特生物药业有限责任公司
1
CXSL2501115
注射用BL-B01D1
成都百利多特生物药业有限责任公司
1
CXSL2501114
注射用BL-B01D1
成都百利多特生物药业有限责任公司
1
CXSL2501113
注射用BL-B01D1
成都百利多特生物药业有限责任公司
1
CXSL2501112
注射用BL-B01D1
成都百利多特生物药业有限责任公司
1
CXSL2501105
注射用BL-B01D1
成都百利多特生物药业有限责任公司
1
CXSL2501104
注射用BL-B01D1
成都百利多特生物药业有限责任公司
1
CXSL2501102
注射用BL-B01D1
成都百利多特生物药业有限责任公司
1
CXSL2501101
注射用LNF2105
山东新时代药业有限公司
1
CXSL2501107
注射用BL-M11D1
成都百利多特生物药业有限责任公司
1
CXSL2501099
SHR-1819注射液
广东恒瑞医药有限公司
1
CXSL2501097
SHR-1905注射液
广东恒瑞医药有限公司
1
CXSL2501096
JMT206注射液
上海津曼特生物科技有限公司
1
CXSL2501094
注射用IMM0306S
宜明昂科生物医药技术(上海)股份有限公司
1
CXSL2501092
注射用DB-1324
映恩生物制药(苏州)有限公司
1
CXSL2501090
JSKN027注射液
江苏康宁杰瑞生物制药有限公司
1
CXSL2501089
AT03-65
泰诚思(上海)生物医药有限公司
1
CXSL2501085
GB19注射液
深圳科兴药业有限公司
1
CXSL2501081
靶向BCMA的嵌合抗原受体T细胞注射液
深圳普瑞金生物药业股份有限公司
1
CXSL2501059
PA3-17注射液
博生吉安科细胞技术有限公司
1
CXSL2501040
GKL-006Allo注射液
北京基因启明生物科技有限公司
1
CXSL2501035
脐带血巨核细胞注射液
苏州血霁生物科技有限公司
1
CXSL2501033
BPAb002注射液
博品泽荣(深圳)生物医药科技有限公司
1
CXSL2501032
注射用BAT1006
百奥泰生物制药股份有限公司
2.4
CXSL2501128
仿制药申请
药品名称
企业
注册分类
受理号
己酮可可碱缓释片
海南皇隆制药股份有限公司
3
CYHS2403772
己酮可可碱注射液
国药集团容生制药有限公司
3
CYHS2403651
硝普钠注射液
成都瑞尔医药科技有限公司
3
CYHS2403556
盐酸多沙普仑注射液
石家庄四药有限公司
3
CYHS2403501
己酮可可碱缓释片
江苏慧聚药业股份有限公司
3
CYHS2403327
醋酸钠林格注射液
西安京西双鹤药业有限公司
3
CYHS2403272
法莫替丁注射液
珠海横琴国研医药科技有限公司
3
CYHS2403065
酮咯酸氨丁三醇注射液
广州艾格生物科技有限公司
3
CYHS2403069
甲氨蝶呤片
南京泽恒医药技术开发有限公司
3
CYHS2402978
维生素B6注射液
国仁健康制药(北京)有限公司
3
CYHS2402833
己酮可可碱缓释片
本溪匠成医药科技有限公司
3
CYHS2402832
二羟丙茶碱注射液
云南药科院生物医药股份有限公司
3
CYHS2402813
布美他尼注射液
四川沃翔生物医药有限公司
3
CYHS2402684
硝酸甘油注射液
陕西顿斯制药有限公司
3
CYHS2402667
硝酸甘油注射液
陕西顿斯制药有限公司
3
CYHS2402666
依帕司他片
焦作市明仁天然药物有限责任公司
3
CYHS2402647
呋塞米注射液
江苏润恒制药有限公司
3
CYHS2402642
二氟尼柳片
浙江赛默制药有限公司
3
CYHS2402617
注射用左亚叶酸钙
石家庄四药有限公司
3
CYHS2402504
己酮可可碱注射液
本溪匠成医药科技有限公司
3
CYHS2402334
门冬氨酸钾注射液
海韬新药研发(江苏)有限公司
3
CYHS2402191
复方醋酸钠林格注射液
安徽丰原药业股份有限公司
3
CYHS2402119
复方醋酸钠林格注射液
安徽丰原药业股份有限公司
3
CYHS2402118
己酮可可碱注射液
江西泰吉立生物医药科技有限公司
3
CYHS2402024
吸入用盐酸丙卡特罗溶液
南京恒道医药科技股份有限公司
3
CYHS2401928
吸入用盐酸丙卡特罗溶液
南京恒道医药科技股份有限公司
3
CYHS2401927
叶酸片
河北爱普制药有限公司
3
CYHS2401903
复合磷酸氢钾注射液
山东华鲁制药有限公司
3
CYHS2401893
氨磺必利口服溶液
宏越科技(湖州)有限公司
3
CYHS2401713
腺苷钴胺胶囊
浙江昂利康制药股份有限公司
3
CYHS2401689
乙酰半胱氨酸注射液
江苏迪赛诺制药有限公司
3
CYHS2401681
阿仑膦酸钠口服溶液
山东如至生物医药科技有限公司
3
CYHS2401335
氯硝西泮注射液
国药集团国瑞药业有限公司
3
CYHS2401176
盐酸氨溴索滴剂
广西维威制药有限公司
3
CYHS2400423
盐酸氨溴索滴剂
广西维威制药有限公司
3
CYHS2400422
米诺地尔外用溶液
北京诚济制药股份有限公司
3
CYHS2303403
米诺地尔外用溶液
北京诚济制药股份有限公司
3
CYHS2303402
氧
重庆神洲气体有限公司
4
CYHS2501575
依折麦布片
江西施美药业股份有限公司
4
CYHS2404533
比索洛尔氨氯地平片
江苏德源药业股份有限公司
4
CYHS2404456
双氯芬酸钠缓释片
四川依科制药有限公司
4
CYHS2404346
伏立康唑片
天津力生制药股份有限公司
4
CYHS2404240
伏立康唑片
天津力生制药股份有限公司
4
CYHS2404239
苯磺酸左氨氯地平片
四川新斯顿制药股份有限公司
4
CYHS2404138
盐酸奥布卡因滴眼液
齐鲁制药有限公司
4
CYHS2404073
硫酸氨基葡萄糖胶囊
广州博济生物医药科技园有限公司
4
CYHS2404047
拉莫三嗪片
辰欣药业股份有限公司
4
CYHS2403999
拉莫三嗪片
辰欣药业股份有限公司
4
CYHS2403998
盐酸阿莫罗芬搽剂
合肥启旸生物医药科技有限公司
4
CYHS2403920
艾拉莫德片
江西科伦药业有限公司
4
CYHS2403842
黄体酮软胶囊
浙江高跖医药科技股份有限公司
4
CYHS2403813
黄体酮软胶囊
浙江高跖医药科技股份有限公司
4
CYHS2403812
枸橼酸钠血滤置换液
宁波泰瑞斯科技有限公司
4
CYHS2403725
布洛芬缓释胶囊
国大(吉林)制药集团有限公司
4
CYHS2403670
卡维地洛片
重庆士立德医药科技有限公司
4
CYHS2403674
达格列净片
石家庄市华新药业有限责任公司
4
CYHS2403658
替米沙坦片
江苏长江药业有限公司
4
CYHS2403543
非布司他片
四川新斯顿制药股份有限公司
4
CYHS2403527
氯雷他定糖浆
拜耳医药(上海)有限公司
4
CYHS2403499
氯雷他定糖浆
拜耳医药(上海)有限公司
4
CYHS2403498
恩他卡朋片
山东新华制药股份有限公司
4
CYHS2403452
硫酸镁钠钾口服用浓溶液
长兴制药股份有限公司
4
CYHS2403420
平衡盐溶液(供灌注用)
沈阳兴齐眼药股份有限公司
4
CYHS2403356
比索洛尔氨氯地平片
广东方盛健盟药业有限公司
4
CYHS2403336
阿奇霉素干混悬剂
北京四环科宝制药股份有限公司
4
CYHS2403308
精氨酸布洛芬颗粒
仁合益康汇泽药业河北有限公司
4
CYHS2403232
精氨酸布洛芬颗粒
仁合益康汇泽药业河北有限公司
4
CYHS2403231
维生素B12滴眼液
成都普什制药有限公司
4
CYHS2403162
青霉素V钾片
广东万泰科创药业有限公司
4
CYHS2403137
青霉素V钾片
广东万泰科创药业有限公司
4
CYHS2403136
硫酸镁钠钾口服用浓溶液
浙江领创优品药业有限公司
4
CYHS2403109
注射用硫酸艾沙康唑
内蒙古白医制药股份有限公司
4
CYHS2403092
地奈德洗剂
江苏知原药业股份有限公司
4
CYHS2403067
盐酸阿莫罗芬搽剂
景时(杭州)药业有限公司
4
CYHS2402882
二甲双胍恩格列净片
烟台鲁银药业有限公司
4
CYHS2402875
丙戊酸钠缓释片(I)
四川科瑞德制药股份有限公司
4
CYHS2402703
富马酸伏诺拉生片
浙江东亚药业股份有限公司
4
CYHS2402677
富马酸伏诺拉生片
浙江东亚药业股份有限公司
4
CYHS2402676
碘普罗胺注射液
北京北陆药业股份有限公司
4
CYHS2402660
氯雷他定糖浆
浙江普利药业有限公司
4
CYHS2402652
氯雷他定糖浆
湖北康源药业有限公司
4
CYHS2402532
氨甲环酸片
浙江赛默制药有限公司
4
CYHS2402436
布瑞哌唑片
哈尔滨珍宝制药有限公司
4
CYHS2402317
布瑞哌唑片
哈尔滨珍宝制药有限公司
4
CYHS2402315
注射用尼可地尔
西安力邦联盟医疗科技有限公司
4
CYHS2402183
注射用尼可地尔
西安力邦联盟医疗科技有限公司
4
CYHS2402182
注射用尼可地尔
西安力邦联盟医疗科技有限公司
4
CYHS2402181
碳酸镧咀嚼片
浙江中同药业有限公司
4
CYHS2402126
沙格列汀二甲双胍缓释片
山东淄博新达制药有限公司
4
CYHS2401959
阿达帕林凝胶
华润三九医药股份有限公司
4
CYHS2401883
注射用尼可地尔
山东新华鲁抗医药有限公司
4
CYHS2401820
碳酸司维拉姆片
浙江昂利康制药股份有限公司
4
CYHS2401665
氨甲环酸注射液
海南爱科制药有限公司
4
CYHS2401035
氨甲环酸注射液
海南爱科制药有限公司
4
CYHS2401034
注射用卡非佐米
杭州中美华东制药有限公司
4
CYHS2400697
妥布霉素地塞米松滴眼液
中山万汉制药有限公司
4
CYHS2400587
德谷胰岛素注射液
珠海联邦生物医药有限公司
3.3
CXSS2400110
德谷胰岛素注射液
珠海联邦生物医药有限公司
3.3
CXSS2400109
达普司他片
安徽宏业药业有限公司
3
CYHL2500235
达普司他片
安徽宏业药业有限公司
3
CYHL2500234
达普司他片
安徽宏业药业有限公司
3
CYHL2500233
托吡司特片
鲁南贝特制药有限公司
3
CYHL2500232
托吡司特片
鲁南贝特制药有限公司
3
CYHL2500231
氟[18F]妥西吡注射液
杭州亦立医药有限公司
3
CYHL2500226
贝美前列素涂剂
南京正科医药股份有限公司
3
CYHL2500228
双丙戊酸钠缓释片
山东信谊制药有限公司
3
CYHL2500224
双丙戊酸钠缓释片
山东信谊制药有限公司
3
CYHL2500223
茚达特罗莫米松吸入粉雾剂(III)
北京抗创联生物制药技术研究有限公司
4
CYHL2500220
茚达特罗莫米松吸入粉雾剂(II)
北京抗创联生物制药技术研究有限公司
4
CYHL2500219
奥洛他定莫米松鼻喷雾剂
长风药业股份有限公司
4
CYHL2500215
奥洛他定莫米松鼻喷雾剂
长风药业股份有限公司
4
CYHL2500214
人凝血因子IX
山东泰邦生物制品有限公司
3.2
CXSL2501068
QL2109注射液
齐鲁制药有限公司
3.3
CXSL2501120
SYS6053
石药集团巨石生物制药有限公司
3.3
CXSL2501095
IBI3035
信达生物制药(苏州)有限公司
3.3
CXSL2501051
进口申请
药品名称
企业
注册分类
受理号
盐酸氨酮戊酸己酯软膏光动力治疗系统
ASIERIS MEDITECH (Hong Kong) CO., LIMITED
2.2;2.4
JXHS2400035
玛巴洛沙韦干混悬剂
Roche Pharma (Schweiz) AG
5.1
JXHS2500090
度普利尤单抗注射液
Sanofi Winthrop Industrie
2.2
JXSS2500026
度普利尤单抗注射液
Sanofi Winthrop Industrie
2.2
JXSS2500025
依柯胰岛素司美格鲁肽注射液
Novo Nordisk A/S
2.3
JXSS2400110
依柯胰岛素司美格鲁肽注射液
Novo Nordisk A/S
2.3
JXSS2400109
依柯胰岛素司美格鲁肽注射液
Novo Nordisk A/S
2.3
JXSS2400106
度普利尤单抗注射液
Sanofi Winthrop Industrie
3.1
JXSS2500060
度普利尤单抗注射液
Sanofi Winthrop Industrie
3.1
JXSS2500059
度普利尤单抗注射液
Sanofi Winthrop Industrie
3.1
JXSS2500058
度普利尤单抗注射液
Sanofi Winthrop Industrie
3.1
JXSS2500057
替莫唑胺胶囊
SUN PHARMACEUTICAL INDUSTRIES LTD.
5.2
JYHS2300117
MK-1084片
Merck Sharp & Dohme LLC
1
JXHL2500395
MK-1084片
Merck Sharp & Dohme LLC
1
JXHL2500394
Zorevunersen注射液
Stoke Therapeutics, Inc.
1
JXHL2500393
Zorevunersen注射液
Stoke Therapeutics, Inc.
1
JXHL2500392
DAK539片
Novartis Pharma AG
1
JXHL2500391
DAK539片
Novartis Pharma AG
1
JXHL2500390
AZD5305
AstraZeneca AB
1
JXHL2500389
ACYW群脑膜炎球菌多糖结合疫苗
Sanofi Pasteur Inc.
3.1
JXSL2500237
Frexalimab注射液
Sanofi-Aventis Recherche & Developpement
1
JXSL2500245
注射用MK-2400
Merck Sharp & Dohme LLC
1
JXSL2500244
人源化抗BTN1A1单克隆抗体
STCube, Inc.
1
JXSL2500242
MK-3475A注射液
Merck Sharp & Dohme B.V.
2.2
JXSL2500248
MK-3475A注射液
Merck Sharp & Dohme B.V.
2.2
JXSL2500247
伊奈利珠单抗注射液
Amgen Inc.
2.2
JXSL2500246
TAK-755
Takeda Development Center Americas, Inc.
2.2
JXSL2500241
泰它西普注射液
Vor Biopharma Inc.
2.2;2.1
JXSL2500243
甲苯磺酸妥舒沙星细粒剂
TOWA PHARMACEUTICAL CO., LTD.
5.2
JYHL2500002
中药相关申请
药品名称
企业
注册分类
受理号
GPN01020胶囊
西安碑林药业股份有限公司
1.1
CXZL2500132
小儿润通糖浆
苏州玉森新药开发有限公司
1.1
CXZL2500128
清胆止痒颗粒
苏州玉森新药开发有限公司
1.1
CXZL2500126
苓桂术甘颗粒
神威药业集团有限公司
3.1
CXZS2500024
真武颗粒
康普药业股份有限公司
3.1
CXZS2500007
桃核承气颗粒
广东一方制药有限公司
3.1
CXZS2400028
注：橙色字体部分结论为不批准或收到通知件；
上市批准
2026-03-06
Journal of Antimicrobial Chemotherapy Volume 81, Issue 1抗菌化疗杂志81卷 1期
https://academic.oup.com/jac/issue
50th Anniversary Collection
50周年纪念合集
Review（综述）
1
Artificial intelligence for improving decision-making in bacterial infection management: a narrative review
人工智能在改善细菌感染治疗决策中的应用：一项叙述性综述
Anisia Talianu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf470, https://doi.org/10.1093/jac/dkaf470
Reviews（综述）
2
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America
耐甲氧西林中间型葡萄球菌的演变格局：欧洲、亚洲和北美洲新流行浪潮的出现
Lillian Rose Giarratana and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf340, https://doi.org/10.1093/jac/dkaf340
3
Azithromycin resistance in non-typhoidal Salmonella: a review
非伤寒沙门氏菌对阿奇霉素的耐药性：综述
Zhe Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf341, https://doi.org/10.1093/jac/dkaf341
4
Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications
抗生素药效动力学：从最低抑菌浓度到高级指标及其应用
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf374, https://doi.org/10.1093/jac/dkaf374
5
Progress in the study of drug resistance mechanism of Bacillus cereus
蜡样芽孢杆菌耐药机制研究进展
Yuhang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf399, https://doi.org/10.1093/jac/dkaf399
6
The curious constraints on clofazimine
氯法齐明的奇特限制
Maple Goh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf430, https://doi.org/10.1093/jac/dkaf430
7
Antiplasmid systems: a novel strategy to combat antibiotic resistance
抗质粒系统：对抗抗生素耐药性的新策略
Mohd Asim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf472, https://doi.org/10.1093/jac/dkaf472
Systematic Review（系统综述）
8
Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes
欧洲球孢子菌病：流行病学、治疗和预后的系统文献综述
Priya Shastri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf407, https://doi.org/10.1093/jac/dkaf407
9
Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method
用标准方法分析小鼠大腿和空心纤维剂量分次研究中的抗菌药物药代动力学/药效动力学指数的系统综述
Najla Alabdulkarim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf446, https://doi.org/10.1093/jac/dkaf446
Virtual Roundtable（虚拟圆桌会议）
10
Procalcitonin in the management of lower respiratory tract infection and sepsis
降钙素原在下呼吸道感染和败血症治疗中的应用
Ramy H Elshaboury and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf298, https://doi.org/10.1093/jac/dkaf298
Original Research（论著）
11
Model-based assessment of letermovir pharmacokinetics in allogeneic haematopoietic stem cell transplant recipients
来特莫韦在异基因造血干细胞移植受者中药代动力学的基于模型的评估
Chrisoula Tahtsidou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf427, https://doi.org/10.1093/jac/dkaf427
12
In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis
体外试验评估依拉环素（CF-301）对甲氧西林敏感或甲氧西林耐药金黄色葡萄球菌及凝固酶阴性葡萄球菌（从感染性心内膜炎患者中分离）的活性
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf435, https://doi.org/10.1093/jac/dkaf435
13
Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study
评估皮下注射阿莫西林/克拉维酸药代动力学作为老年患者静脉给药替代方案——PhASAge研究
Nicolas Grégoire and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf381, https://doi.org/10.1093/jac/dkaf381
14
Real-life use of isavuconazole in Spanish children and adolescents
西班牙儿童和青少年中艾沙康唑的实际使用情况
Natalia Mendoza-Palomar and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf394, https://doi.org/10.1093/jac/dkaf394
15
No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis
基于FAERS数据库的不成比例性分析：未发现甘氨酰环素类与颅内高压相关的药物警戒信号
Slobodan M Jankovic and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf395, https://doi.org/10.1093/jac/dkaf395
16
Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet
成人经肠内营养管给予泊沙康唑：口服混悬液与碾碎的缓释片的药代动力学目标达成情况比较
Nirjan Bhattarai and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf396, https://doi.org/10.1093/jac/dkaf396
17
Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies
CYP3A4介导的药物相互作用特征：一项关于泊沙康唑和鲁索替尼在血液系统恶性肿瘤中的固定序列药代动力学中国研究
Beibei Liang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf398, https://doi.org/10.1093/jac/dkaf398
18
Differences in prescription for impetigo and cellulitis across years in three European countries
三个欧洲国家不同年份脓疱病和蜂窝织炎的处方差异
Thomas Bettuzzi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf400, https://doi.org/10.1093/jac/dkaf400
19
β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit
重症监护室社区获得性脓毒症早期阶段监测的β-内酰胺浓度
Karolina Liljedahl Prytz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf401, https://doi.org/10.1093/jac/dkaf401
20
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
在空心纤维系统中，模拟吸入氯法齐明与口服氯法齐明联合阿奇霉素和乙胺丁醇的抗结核分枝杆菌疗效增强比较
Jelmer Raaijmakers and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf402, https://doi.org/10.1093/jac/dkaf402
21
Identification of antimicrobial resistance genes in Escherichia coli through network diffusion
通过网络扩散法鉴定大肠杆菌中的抗生素耐药基因
Anis Mansouri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf404, https://doi.org/10.1093/jac/dkaf404
22
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease
依培硼罗在脓肿分枝杆菌肺病空心纤维系统模型中的临床前评估
Sanjay Singh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf405, https://doi.org/10.1093/jac/dkaf405
23
The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization
β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度（MICcBLI）作为评估哌拉西林/他唑巴坦药代动力学/药效动力学关系以优化给药的方法
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf406, https://doi.org/10.1093/jac/dkaf406
24
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction
解析铜绿假单胞菌AmpC诱导过程中青霉素结合蛋白、β-内酰胺酶活性和mRNA动态的三元关系
Maria Montaner and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf408, https://doi.org/10.1093/jac/dkaf408
25
Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge
不同地区万古霉素可变型粪肠球菌菌株中线性VanA质粒的未被察觉的传播：一项诊断挑战
Ana C Almeida-Santos and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf409, https://doi.org/10.1093/jac/dkaf409
26
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study
在病毒学抑制的HIV感染者中从依曲韦林切换至多拉韦林：法国多中心SWEED观察性研究的结果
Romain Palich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf410, https://doi.org/10.1093/jac/dkaf410
27
HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda
乌干达多替拉韦时代孕产妇及哺乳期母亲中HIV-1耐药情况及其与儿童HIV感染的关联
Anne Kapaata and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf411, https://doi.org/10.1093/jac/dkaf411
28
Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States
美国威斯康星州农村地区高风险成人因呼吸道合胞病毒、流感或人偏肺病毒感染就诊时的门诊抗生素处方情况
Sarah C J Jorgensen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf412, https://doi.org/10.1093/jac/dkaf412
29
Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies
奥马环素作为鸟分枝杆菌感染候选药物：单药及联合治疗的体外研究
Saskia E Mudde and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf413, https://doi.org/10.1093/jac/dkaf413
30
Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022–2023)
后疫情时代美国成人侵袭性与非侵袭性肺炎链球菌病血清型流行病学及抗生素敏感性趋势（2022-2023）
Mekki F Bensaci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf414, https://doi.org/10.1093/jac/dkaf414
31
Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions
慢性恰加斯病患者苯芴醇药代动力学：与人口统计学因素及药物不良反应的关联
Gabriel P E Silveira and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf416, https://doi.org/10.1093/jac/dkaf416
32
Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis
博德特氏菌属中获得的抗菌药物耐药基因：全球基因组分析
Biao Tang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf418, https://doi.org/10.1093/jac/dkaf418
33
Machine learning for personalized antimicrobial susceptibility breakpoints: (Adaptive clinical breakpoint interpretation)
基于机器学习的个性化抗菌药物敏感性折点制定（自适应临床折点解释）
Yinzheng Zhong and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf419, https://doi.org/10.1093/jac/dkaf419
34
Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights
印度异常威克汉姆酵母菌血症的多中心研究：新发耐药性及机制洞察
Shristi Verma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf420, https://doi.org/10.1093/jac/dkaf420
35
Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations
减少氨曲南/阿维巴坦浪费：蒙特卡洛模拟的启示
Yeleen Fromage and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf421, https://doi.org/10.1093/jac/dkaf421
36
Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates
基于纳米颗粒的环丙沙星与美罗培南共递送可增强对多重耐药高毒力肺炎克雷伯菌临床分离株的协同活性
Reham Mostafa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf422, https://doi.org/10.1093/jac/dkaf422
37
Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing
危重症儿童及青年总游离哌拉西林群体药代动力学模型开发：用于蒙特卡洛模拟及模型引导的精准给药
Sonya Tang Girdwood and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf423, https://doi.org/10.1093/jac/dkaf423
38
Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients
达标分析：住院患者达到目标万古霉素血浆浓度所需的时间与剂量
W Töpfer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf424, https://doi.org/10.1093/jac/dkaf424
39
Notable transmitted HIV drug resistance among people who inject drugs in Pakistan
巴基斯坦注射毒品人群中显著传播的HIV耐药性
Stephanie Melnychuk and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf425, https://doi.org/10.1093/jac/dkaf425
40
Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium
协同但临床难以实现：阿莫西林/头孢曲松联合对氨苄西林敏感粪肠球菌的体外活性
Ahmed Ashrin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf426, https://doi.org/10.1093/jac/dkaf426
41
Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase–producing Gram-negative bacteria in a neutropenic murine thigh infection model
中性粒细胞减少小鼠大腿感染模型中他尼硼巴坦（VNRX-5133）联合头孢吡肟对产β-内酰胺酶革兰氏阴性菌的药效动力学研究
Panagiota-Christina Georgiou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf431, https://doi.org/10.1093/jac/dkaf431
42
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.
非塞拉蒂亚属肠杆菌目细菌所致心内膜炎的流行病学及治疗
Clayton F Hausberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf432, https://doi.org/10.1093/jac/dkaf432
43
Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus
阿普拉霉素及其组合对脓肿分枝杆菌的增强活性
Yanqin Huang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf433, https://doi.org/10.1093/jac/dkaf433
44
Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene
印度毛癣菌与红色毛癣菌中由ABC转运蛋白和MFS基因介导的流出泵型多重耐药机制
Dipika Shaw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf434, https://doi.org/10.1093/jac/dkaf434
45
Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases
鞘氨醇杆菌属作为SPI Ambler B类金属β-内酰胺酶的固有产生者
Delphine Girlich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf436, https://doi.org/10.1093/jac/dkaf436
46
Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli
blaNDM-1阳性碳青霉烯耐药溶胶阿卡净菌的全球系统发育地理学及基因组特征
Pengpeng Min and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf437, https://doi.org/10.1093/jac/dkaf437
47
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients
血液透析患者潜伏性结核治疗中每月一次每日利福喷丁的药代动力学及耐受性
Thornthun Ueaphongsukkit and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf439, https://doi.org/10.1093/jac/dkaf439
48
In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales
头孢吡肟-恩美他唑巴坦、头孢吡肟-他尼硼巴坦及头孢吡肟-齐德巴坦对产碳青霉烯酶肠杆菌目的体外敏感性
Marion Dutkiewicz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf440, https://doi.org/10.1093/jac/dkaf440
49
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates
舒巴坦/杜洛巴坦联合β-内酰胺类抗生素对澳大利亚脓肿分枝杆菌分离株的体外疗效
Kirby Patterson-Fahy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf441, https://doi.org/10.1093/jac/dkaf441
50
Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate
利用CRISPR-Cas9及CRISPRi系统逆转临床多重耐药大肠杆菌分离株的抗生素耐药性
Ruonan Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf442, https://doi.org/10.1093/jac/dkaf442
51
Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?
重症监护室中复方磺胺甲噁唑的应用：固定组合在现实中的不可行性？
Manon Launay and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf443, https://doi.org/10.1093/jac/dkaf443
52
National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
哥伦比亚全国代表性调查：基于下一代测序的抗逆转录病毒耐药相关突变分析
Ernesto Martínez-Buitrago and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf444, https://doi.org/10.1093/jac/dkaf444
53
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens
基于模型的含固定剂量多替拉韦方案减量策略比较
Laura Dickinson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf445, https://doi.org/10.1093/jac/dkaf445
54
Therapeutic drug monitoring and target attainment of unbound flucloxacillin in hospitalized patients with measured MICs (FLUTE)
住院患者中游离氟氯西林的治疗药物监测及目标达成情况（基于实测最低抑菌浓度的FLUTE研究）
Pjotr P Temme and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf447, https://doi.org/10.1093/jac/dkaf447
55
Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes
奈玛特韦/利托那韦纳入急症治疗目录：一项多中心回顾性评估定量经济与定性临床结果的研究
Jose Valdes Ledesma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf448, https://doi.org/10.1093/jac/dkaf448
56
Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study
采用批量质量保证抽样法对养老院进行本地抗生素耐药性监测的可行性研究
Sacha Kuil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf451, https://doi.org/10.1093/jac/dkaf451
57
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24
2021-2024年，在世卫组织三个区域的八个世卫组织增强淋球菌抗菌药物监测计划国家中，新型抗菌药物吉皮达星对淋病奈瑟菌分离株的体外活性较高
Josefine Ahlstrand and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf452, https://doi.org/10.1093/jac/dkaf452
58
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable
尽管整合酶抑制剂用于治疗HIV感染的使用量不断增加，但此类药物的耐药性仍保持稳定
Cathia Soulie and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf454, https://doi.org/10.1093/jac/dkaf454
59
Fine-needle aspiration in infected necrotizing pancreatitis in the delayed intervention era: a post hoc analysis of safety, microbiological yield and therapeutic implications
延迟干预时代感染性坏死性胰腺炎的细针穿刺抽吸术：安全性、微生物学检出率及治疗意义的事后分析
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf455, https://doi.org/10.1093/jac/dkaf455
60
β-Lactam dosing in critically ill children: predictors for target non-attainment
危重症儿童β-内酰胺类药物给药：未达目标浓度的预测因素
Stef Schouwenburg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf457, https://doi.org/10.1093/jac/dkaf457
61
Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis
实体器官移植患者合并侵袭性曲霉病住院时三唑类药物与钙调磷酸酶抑制剂或哺乳动物雷帕霉素靶蛋白抑制剂的联合用药情况
Barbara Alexander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf461, https://doi.org/10.1093/jac/dkaf461
62
In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes
携带最常见碳青霉烯酶基因的鲍曼不动杆菌中头孢地尔耐药突变体的体外筛选
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf462, https://doi.org/10.1093/jac/dkaf462
63
Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input
预防产OXA β-内酰胺酶铜绿假单胞菌感染耐药性的产生：将临床结局与中空纤维模型输入相关联
María M Montero and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf464, https://doi.org/10.1093/jac/dkaf464
64
A national pilot community pharmacy–led urinary tract infection service: clinical and patient-reported outcomes from 9077 consultations
全国社区药房主导的尿路感染服务试点项目：9077次咨询的临床结局和患者报告结局
Efi Mantzourani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf466, https://doi.org/10.1093/jac/dkaf466
65
Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus
提高转化价值：针对活跃增殖、营养匮乏和生物膜包裹的脓肿分枝杆菌进行临床前药物活性测试
Henriëtte M Meliefste and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf468, https://doi.org/10.1093/jac/dkaf468
Research Letters（研究快报）
66
Novel multiresistance transposon Tn7731 in bovine Pasteurella multocida from Germany
德国牛源多杀性巴氏杆菌中新型多重耐药转座子Tn7731
Henrike Krüger-Haker and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf336, https://doi.org/10.1093/jac/dkaf336
67
Efficacy of eravacycline in difficult-to-treat (DTR) Acinetobacter baumannii bacteraemia in ICU: a case report
厄他培南治疗重症监护病房难治性鲍曼不动杆菌菌血症的疗效：一例病例报告
Monica Melchio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf347, https://doi.org/10.1093/jac/dkaf347
68
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
来特莫韦暴露的造血细胞移植受者中EB病毒感染和移植后淋巴增殖性疾病风险可能增加
Jose F Camargo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf348, https://doi.org/10.1093/jac/dkaf348
69
Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring
达巴万星在严重体重不足人工瓣膜心内膜炎女性患者中的给药：主动治疗药物监测的关键作用
Ambra Barco and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf365, https://doi.org/10.1093/jac/dkaf365
70
Cefazolin-induced seizures in a haemodialysis patient with elevated serum and cerebrospinal fluid concentrations: a case report
血液透析患者头孢唑林血清和脑脊液浓度升高诱发癫痫：一例病例报告
Kohei Hasegawa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf373, https://doi.org/10.1093/jac/dkaf373
71
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
使用聚丙烯腈膜进行连续性肾脏替代治疗的患者中卡泊芬净药代动力学治疗监测的回顾性分析
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf390, https://doi.org/10.1093/jac/dkaf390
72
Diffusion of OXA-48- and NDM-5-producing Klebsiella pneumoniae ST383 clone in Central Italy
产OXA-48和NDM-5的肺炎克雷伯菌ST383克隆在意大利中部的传播
Gloria D’Achille and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf397, https://doi.org/10.1093/jac/dkaf397
73
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry
来那卡帕韦在病毒载量阳性且接受过大量抗逆转录病毒治疗的HIV感染者中的持久性：来自PRESTIGIO登记处的现实数据
Tommaso Clemente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf415, https://doi.org/10.1093/jac/dkaf415
74
Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker
猪场工人利奈唑胺耐药猪鼻支原体分离株中噁唑烷酮类耐药基因cfr和optrA的共携带情况
Gi Yong Lee and Soo-Jin Yang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf428, https://doi.org/10.1093/jac/dkaf428
75
Importance of reviewing the package insert from gradient strip manufacturers
梯度扩散法药敏纸片生产商说明书审阅的重要性
Mandy Wootton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf429, https://doi.org/10.1093/jac/dkaf429
76
One resistance gene, many transposons: repeated formation of compound and pseudo-compound transposons carrying the aphA1 kanamycin and neomycin resistance gene
一个耐药基因，多个转座子：携带aphA1卡那霉素和新霉素耐药基因的复合及假复合转座子的重复形成
Christopher J Harmer and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf450, https://doi.org/10.1093/jac/dkaf450
77
Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis
接受暴露后多西环素预防性治疗的暴露前预防用药男男性行为者中未发现性病淋巴肉芽肿
Cristina Gómez-Ayerbe and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf456, https://doi.org/10.1093/jac/dkaf456
78
In vitro activity of gepotidacin against Chlamydia trachomatis
吉皮达星对沙眼衣原体的体外活性
Arabella Touati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf460, https://doi.org/10.1093/jac/dkaf460
Journal of Antimicrobial Chemotherapy Volume 81, Issue 2抗菌化疗杂志 81卷 2期
https://academic.oup.com/jac/issue
Viewpoints（观点）
1
Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
长效糖肽类：最需要它们的患者获取药物的障碍有哪些，如何克服？
Aleece MacPhail and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf471, https://doi.org/10.1093/jac/dkaf471
2
Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies
靶向治疗时代急性白血病抗真菌预防的重新定义
Marcio Nucci and Johan Maertens
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag010, https://doi.org/10.1093/jac/dkag010
Reviews（综述）
3
Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae
替加环素对肺炎克雷伯菌的耐药机制及临床疗效研究进展
Meilin Wu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf504, https://doi.org/10.1093/jac/dkaf504
4
Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations
两性霉素B脂质体与肾脏安全性：证据回顾及临床考量
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf473, https://doi.org/10.1093/jac/dkaf473
5
Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era
奥密克戎时代减轻血液系统恶性肿瘤患者严重新冠肺炎的策略
Keiji Okinaka and Joshua T Schiffer
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf489, https://doi.org/10.1093/jac/dkaf489
Systematic Reviews（系统综述）
6
Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis
吉泊替达辛治疗尿路感染的安全性和有效性：一项基于GRADE评估的系统综述和荟萃分析
Taha Ibrahim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf469, https://doi.org/10.1093/jac/dkaf469
7
The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review
产吲哚金黄杆菌日益凸显的临床相关性和抗菌药物耐药性：一项系统综述
Bruna Abdul Ahad Saad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf476, https://doi.org/10.1093/jac/dkaf476
8
A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae
决定肺炎克雷伯菌多粘菌素耐药性的突变谱综合分析
Sambit Kumar Dwibedy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf503, https://doi.org/10.1093/jac/dkaf503
9
Factors promoting or hindering self-administered outpatient parenteral antimicrobial therapy: a systematic literature review
促进或阻碍自我给药门诊静脉注射抗菌药物治疗的因素：一项系统文献综述
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf490, https://doi.org/10.1093/jac/dkaf490
Original Research（论著）
10
Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics
头孢吡肟/恩美唑巴坦治疗革兰氏阴性假体周围关节感染？一项关于猪的靶组织药代动力学的随机研究
M B D Nielsen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf487, https://doi.org/10.1093/jac/dkaf487
11
Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients
体外膜肺氧合模式对危重患者伏立康唑暴露的影响
Xinrui Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf501, https://doi.org/10.1093/jac/dkaf501
12
Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
基于模型通过成人和婴儿群体药代动力学-药效学模型评估VRC07-523LS在婴儿中的给药方案
Dustin Huynh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf449, https://doi.org/10.1093/jac/dkaf449
13
Antibiotic resistance of Pseudomonas aeruginosa strains—intracellular metabolomics analysis
铜绿假单胞菌菌株的抗生素耐药性——细胞内代谢组学分析
Karolina Anna Mielko-Niziałek and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf453, https://doi.org/10.1093/jac/dkaf453
14
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates
头孢吡肟/齐多巴坦对舒巴坦/杜洛巴坦敏感和耐药鲍曼不动杆菌临床分离株的体外活性
Carlo Tascini and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf467, https://doi.org/10.1093/jac/dkaf467
15
Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands
荷兰肺炎支原体大环内酯类抗生素耐药性的流行情况
Patrick D J Sturm and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf475, https://doi.org/10.1093/jac/dkaf475
16
Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant
Acinetobacter baumannii
模拟肺炎患者肺部暴露情况以评估临床替加环素方案对碳青霉烯类耐药鲍曼不动杆菌的抗菌能力和耐药抑制作用
Xiaonan Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf477, https://doi.org/10.1093/jac/dkaf477
17
Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case
加拿大发现携带vanA、optrA和cfr(D)的粪肠球菌线性质粒：一项CANWARD监测病例
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf478, https://doi.org/10.1093/jac/dkaf478
18
The effect of intrauterine exposure to aminoglycosides on neonatal hearing
宫内暴露于氨基糖苷类抗生素对新生儿听力的影响
Daniel Leshin-Carmel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf483, https://doi.org/10.1093/jac/dkaf483
19
Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies
头孢他啶/阿维巴坦：对抗多重耐药铜绿假单胞菌的有力武器——揭示体内外策略
Jiaju Zhuo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf495, https://doi.org/10.1093/jac/dkaf495
20
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints
采用中国CAST折点，比较422株金黄色葡萄球菌对依拉环素的纸片扩散法、最低抑菌浓度测试条法和肉汤微量稀释法的敏感性测试结果
Xinying Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf502, https://doi.org/10.1093/jac/dkaf502
21
Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis
肺炎链球菌性脑膜炎期间达托霉素在脑脊液中的渗透情况
Pascal Chavanet and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf474, https://doi.org/10.1093/jac/dkaf474
22
Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi
用于检测广泛耐药伤寒沙门菌的快速分子诊断技术
Emma L Sweeney and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf481, https://doi.org/10.1093/jac/dkaf481
23
Gender inequality and antibiotic consumption: analysis of pharmaceutical sales data from 70 countries, 2000–22
性别不平等与抗生素消费：基于2000 - 2022年70个国家药品销售数据的分析
Deepshikha Batheja and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag002, https://doi.org/10.1093/jac/dkag002
24
Real-world evaluation of isavuconazole in children with cancer
伊沙康唑在儿童癌症患者中的现实应用评估
Janine Nijhuis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf485, https://doi.org/10.1093/jac/dkaf485
25
Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study
加纳提供细菌学服务的实验室对抗菌药物敏感性试验指南依从性的评估：一项试点研究
Joseph Elikem Efui Acolatse and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag003, https://doi.org/10.1093/jac/dkag003
26
Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan
台湾地区基于多替拉韦或比克替拉韦的抗逆转录病毒治疗失败后，HIV感染者对第二代整合酶抑制剂的耐药性
Guan-Jhou Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf488, https://doi.org/10.1093/jac/dkaf488
27
In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates
吉泊西汀对一组具有挑战性的多重耐药淋病奈瑟菌分离株的体外活性
Michelle Jayne Cole and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag001, https://doi.org/10.1093/jac/dkag001
28
A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database
基于美国食品药品监督管理局（FDA）不良事件报告系统数据库的奥马环素相关不良事件比例失衡分析
Ye-Lei Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag006, https://doi.org/10.1093/jac/dkag006
29
Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
基于体重范围的口服异速缩放米替福新给药方案在儿童内脏利什曼病患者中的简化应用
Andres Mazariegos Herrera and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag014, https://doi.org/10.1093/jac/dkag014
30
evelopment of a capability framework for antimicrobial stewardship specialist health professionals working in the NHS in England: utilizing Delphi methodology
运用德尔菲法为在英国国家医疗服务体系（NHS）中工作的抗菌药物管理专业人员制定能力框架
Ryan A Hamilton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf438, https://doi.org/10.1093/jac/dkaf438
31
First characterization of insertions in the HIV-1 integrase-coding region from people with HIV
首次对来自艾滋病病毒感染者的HIV-1整合酶编码区插入情况进行特征分析
Nhat Quang Tu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf491, https://doi.org/10.1093/jac/dkaf491
32
Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae
开发一种基于阻抗的淋病奈瑟菌快速抗菌药物敏感性检测方法
Caitlin N Daniels and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf493, https://doi.org/10.1093/jac/dkaf493
33
Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats
新型抗疟候选药物Zintrodiazine在Wistar大鼠中的幼年毒性和发育安全性研究
Hitesh A Kadu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag008, https://doi.org/10.1093/jac/dkag008
34
Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents
欧洲抗微生物药物敏感性试验委员会（EUCAST）重新定义的敏感性分类是否需要调整儿童抗生素剂量？——对四种常用药物的实用生理药代动力学建模研究
Marika A de Hoop-Sommen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf463, https://doi.org/10.1093/jac/dkaf463
35
Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study
门诊抗菌治疗（OPAT）服务中开展治疗药物监测（TDM）和精准剂量抗菌治疗的机遇：一项前瞻性观察研究
R C Wilson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf484, https://doi.org/10.1093/jac/dkaf484
36
Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy
性别、年龄和身体成分对接受长效注射用抗逆转录病毒治疗的HIV感染者利匹韦林和卡博特韦谷浓度的影响
Maria Vittoria Cossu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag024, https://doi.org/10.1093/jac/dkag024
37
Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock
头孢地尔在两例感染性休克患者长时间间歇性肾脏替代治疗期间的药代动力学
Julius J Schmidt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf496, https://doi.org/10.1093/jac/dkaf496
38
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
了解铜绿假单胞菌pvdS和fecI突变体对头孢地尔敏感性降低的机制
Yoshinori Yamano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag004, https://doi.org/10.1093/jac/dkag004
39
Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD
基于生物标志物的美罗培南在儿童重症肺炎中的生理药动学模型构建：对靶部位药代动力学/药效学的影响
Yao Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf500, https://doi.org/10.1093/jac/dkaf500
40
Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia
评估接受头孢唑林或抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症患者中，与血液延迟灭菌相关的低白蛋白血症阈值
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf498, https://doi.org/10.1093/jac/dkaf498
Research Letters（研究快讯）
41
False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report
不当使用暴露后预防用药导致第四代HIV筛查试验p24抗原弱检出后出现假阴性结果：一例病例报告
J Kimmerlin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf459, https://doi.org/10.1093/jac/dkaf459
42
Proposal for the nomenclature of tmexCD-toprJ-like gene clusters
关于tmexCD-toprJ样基因簇命名的建议
Chengzhen Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf482, https://doi.org/10.1093/jac/dkaf482
43
IS26-mediated chromosomal integration of virulence plasmid fragments in ST2237 carbapenem-resistant Klebsiella pneumoniae
IS26介导的毒力质粒片段在ST2237型碳青霉烯耐药肺炎克雷伯菌染色体中的整合
Yan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag018, https://doi.org/10.1093/jac/dkag018
Letter to the Editor（致编辑的信）
44
Comment on: Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
对“采用聚丙烯腈膜对接受连续性肾脏替代治疗的患者进行卡泊芬净药代动力学监测的回顾性分析”的评论
Gwénola Marais and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf465, https://doi.org/10.1093/jac/dkaf465
45
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy-right-to-reply
意大利米兰地区使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性传播感染的抗菌药物使用情况——回应说明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag027, https://doi.org/10.1093/jac/dkag027
ACKNOWLEDGEMENT OF REFEREES（鸣谢审稿专家）
46
Acknowledgement of Referees
鸣谢审稿专家
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf417, https://doi.org/10.1093/jac/dkaf417
CORRECTION（更正）
47
Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
更正：关于Evusheld在感染奥密克戎变异株前或奥密克戎变异株的新冠住院患者中的抗病毒效果：对随机DisCoVeRy试验的建模分析的评论
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf492, https://doi.org/10.1093/jac/dkaf492
Journal of Antimicrobial Chemotherapy Volume 81, Issue 3抗菌化疗杂志 81卷 3期
https://academic.oup.com/jac/issue
REVIEW（综述）
1
Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations
缩小欧洲暴露前预防获取差距：面向难以触及（PrEP）人群的公平与创新战略框架
Josep M Llibre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag052, https://doi.org/10.1093/jac/dkag052
2
Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation
成人全身性抗真菌药物的精准给药：治疗药物监测、经验性剂量优化及实施障碍
Daniel B Chastain and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag055, https://doi.org/10.1093/jac/dkag055
3
Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future
细菌DNA拓扑异构酶IV和DNA旋转酶抑制剂：喹诺酮类药物的历史、临床应用及未来潜在替代方案
Daisuke Fukuda and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag054, https://doi.org/10.1093/jac/dkag054
4
Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions
应对多重耐药肺炎克雷伯菌：当前治疗方案与未来方向
Robiul Islam and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag064, https://doi.org/10.1093/jac/dkag064
SYSTEMATIC REVIEW（系统综述）
5
Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
耐碳青霉烯类鲍曼不动杆菌中金属β-内酰胺酶的全球和区域流行情况：一项系统综述和荟萃分析
Stamatis Karakonstantis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag037, https://doi.org/10.1093/jac/dkag037
Original Research（论著）
6
The effect of oral ciprofloxacin at conventional doses on the QT interval in a tertiary outpatient setting
三级门诊常规剂量口服环丙沙星对患者QT间期的影响
Weber Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag020, https://doi.org/10.1093/jac/dkag020
7
Bictegravir concentrations in breastmilk of healthy, lactating women without HIV
未感染人类免疫缺陷病毒（HIV）的健康哺乳期女性乳汁中的比克替拉韦浓度
L C van der Wekken-Pas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag022, https://doi.org/10.1093/jac/dkag022
8
Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study
从深部部位临床标本中分离出的嗜麦芽窄食单胞菌的治疗及转归：一项双中心回顾性队列研究
Anastasia Saade and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag021, https://doi.org/10.1093/jac/dkag021
9
Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study
万古霉素相关急性肾损伤风险预测模型的建立：一项多中心回顾性研究
Tomoyuki Ishigo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag012, https://doi.org/10.1093/jac/dkag012
10
Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure
HIV-1 整合酶天然多态性 K156N 与 3′PPT 突变在多替拉韦单药治疗失败中的协同作用
Jolieke A T van Osch and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag033, https://doi.org/10.1093/jac/dkag033
11
Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies
体重指数和血清白蛋白水平对血液系统恶性肿瘤患者艾沙康唑血浆浓度的影响
Jie Gao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag032, https://doi.org/10.1093/jac/dkag032
12
Pharmacokinetics of cefotaxime and its metabolite desacetyl-cefotaxime to optimize dosing in critically ill children and children with sickle cell disease
用以优化危重症儿童和镰状细胞病儿童给药剂量的头孢噻肟及其代谢产物去乙酰头孢噻肟的药代动力学研究
Seef Abdalla and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag019, https://doi.org/10.1093/jac/dkag019
13
Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24
2017 - 2024年加拿大头孢曲松耐药淋病奈瑟菌情况汇总
Robyn Thorington and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag007, https://doi.org/10.1093/jac/dkag007
14
Improving perioperative prophylactic antibiotic prescribing using a novel decision-support tool
使用新型决策支持工具改进围手术期预防性抗生素处方
Mark Mcintyre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag015, https://doi.org/10.1093/jac/dkag015
15
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study
针对产超广谱AmpC酶的阴沟肠杆菌复合群和产气克雷伯菌临床分离株，比较已上市与新一代β-内酰胺类抗生素的抗菌活性：一项多中心研究
Ángel Rodríguez-Villodres and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag034, https://doi.org/10.1093/jac/dkag034
16
Impact of eravacycline on fibrinogen
依拉环素对纤维蛋白原的影响
Emily Stevenson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag030, https://doi.org/10.1093/jac/dkag030
17
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients
原位肝移植受者连续输注头孢他啶-阿维巴坦的药代动力学/药效学胆系分析：一项病例系列研究
Milo Gatti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag009, https://doi.org/10.1093/jac/dkag009
18
Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates
从肺炎克雷伯菌复合群临床分离株队列中鉴定出由mrkH失活介导的与自动聚集相关的碳青霉烯耐受性
Natsuki Yamanaka and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag017, https://doi.org/10.1093/jac/dkag017
19
In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm
双联和三联抗菌药物组合对碳青霉烯耐药铜绿假单胞菌生物膜的体外活性研究
Si-Ho Kim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag031, https://doi.org/10.1093/jac/dkag031
20
LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state
LYSC98作为一种新型万古霉素衍生物，对耐受状态下的耐药病原体有效
Xing Xia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag036, https://doi.org/10.1093/jac/dkag036
21
HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV
HIV感染者从富马酸替诺福韦二吡呋酯切换为丙酚替诺福韦后，HBV状态对转氨酶下降的调节作用
Giuseppe Lapadula and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag045, https://doi.org/10.1093/jac/dkag045
22
Pharmacokinetics of colistin in adult critically ill patients in South Africa
南非成人危重症患者中多黏菌素的药代动力学研究
Veshni Pillay-Fuentes Lorente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag011, https://doi.org/10.1093/jac/dkag011
23
Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24)
2019 - 2024年中国10家三级医院临床霉菌对奥罗芬净、马诺盖匹克斯、两性霉素B、三唑类和棘白菌素类抗真菌药的敏感性监测
Su Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag016, https://doi.org/10.1093/jac/dkag016
24
Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study
短周期每周三日依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯疗法：一项为期七年的延长研究
Beatriz Borjabad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag040, https://doi.org/10.1093/jac/dkag040
25
Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials
美国感染HIV者启动现代抗逆转录病毒治疗方案后患高血压的风险：五项临床试验血压数据汇总分析
Priscilla Y Hsue and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag005, https://doi.org/10.1093/jac/dkag005
26
Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500mg at days 1, 15 and 43 in bone and joint or cardiovascular infection
采用第1、15和43天各1500毫克的三剂量方案对达巴万星（Dalbavancin）在骨关节或心血管感染治疗中的实际药物监测研究
Thomas Lin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag039, https://doi.org/10.1093/jac/dkag039
27
Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries
撒哈拉以南非洲国家全国范围内的HIV耐药及高病毒载量模式
Abubaker Ibrahim Elbur and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf497, https://doi.org/10.1093/jac/dkaf497
28
Risk factors for suboptimal target attainment of commonly used ß-lactam antibiotics in older adults: a prospective cohort study
老年人常用β-内酰胺类抗生素未达最佳治疗目标的风险因素：一项前瞻性队列研究
Arnaud De Clercq and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag048, https://doi.org/10.1093/jac/dkag048
29
Physiologically based pharmacokinetic modelling to optimize dosing regimen of biapenem in renal impairment and elderly populations
基于生理的药代动力学模型优化肾功能不全及老年人群比阿培南给药方案
Wenyan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf499, https://doi.org/10.1093/jac/dkaf499
30
Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study
快速表型抗菌药物敏感性试验指导下的早期目标性治疗对革兰氏阴性菌血流感染危重患者的效果：一项回顾性队列研究
Salvatore Rotundo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag056, https://doi.org/10.1093/jac/dkag056
31
Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK
与新冠肺炎相关的医疗变化对英国苏格兰地区临床大肠杆菌分离株抗生素耐药性的影响：中断时间序列分析
Laura Ciaccio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag049, https://doi.org/10.1093/jac/dkag049
32
Multicentre evaluation of teicoplanin prescribing and monitoring in the UK and Ireland: the TUcK–SHOP study
英国和爱尔兰替考拉宁处方与监测的多中心评估：TUcK–SHOP研究
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag038, https://doi.org/10.1093/jac/dkag038
33
Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
糖尿病与HIV合并代谢功能障碍相关脂肪性肝病成人患者发生显著肝纤维化的风险：一项前瞻性队列研究
Win Min Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag053, https://doi.org/10.1093/jac/dkag053
34
A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025
基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库2013 - 2025年数据的碳青霉烯类相关药物警戒分析
Connor Frey and Parham Elmi
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag060, https://doi.org/10.1093/jac/dkag060
35
Effects of extracorporeal membrane oxygenation on the pharmacokinetics and tissue penetration rates of vancomycin and linezolid: data from Landrace pigs
体外膜肺氧合对万古霉素和利奈唑胺药代动力学及组织穿透率的影响：来自长白猪的数据
Huifang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag063, https://doi.org/10.1093/jac/dkag063
36
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes
在既往存在耐药突变的人类免疫缺陷病毒（HIV）感染者中换用比克替拉韦/恩曲他滨/丙酚替诺福韦治疗。来自意大利ARCA队列的数据：BIC-BARRIER研究。比克替拉韦/恩曲他滨/丙酚替诺福韦（B/F/TAF）换药方案：耐药突变与治疗结果
Laura Pezzati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag035, https://doi.org/10.1093/jac/dkag035
37
A two-stage diagnostic model for discriminating and assessing risk of meropenem heteroresistance in Pseudomonas aeruginosa
用于鉴别和评估铜绿假单胞菌对美罗培南异质性耐药风险的二阶段诊断模型
Yali Fan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag061, https://doi.org/10.1093/jac/dkag061
38
Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery
微透析评估庆大霉素在腹部手术中作为二线抗菌预防药物的效果
Quentin Saint-Genis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag071, https://doi.org/10.1093/jac/dkag071
39
Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers
伏立康唑药代动力学及肝毒性的遗传和临床预测因素：聚焦于CYP2C19正常代谢型和中间代谢型
Hui Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag065, https://doi.org/10.1093/jac/dkag065
40
Stakeholder perspectives on the offer and acceptance of self-administration of outpatient parenteral antimicrobial therapy: a qualitative study
利益相关者对提供和接受门诊患者自行注射抗菌药物治疗的看法：一项定性研究
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag068, https://doi.org/10.1093/jac/dkag068
41
Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort
当前髋关节和膝关节置换术中氯唑西林预防性用药剂量指南是否充分？来自一项前瞻性瑞典队列研究的证据
Katja Wallander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag067, https://doi.org/10.1093/jac/dkag067
42
Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China
治疗前HIV药物耐药性对开始接受抗逆转录病毒治疗患者的死亡率、失访率和病毒抑制率的影响以及遗传传播网络：中国西南地区一项观察性队列研究
Litai Qin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag073, https://doi.org/10.1093/jac/dkag073
RESEARCH LETTER（研究快讯）
43
Varicella and varicella zoster virus meningoencephalitis in a diffuse large B-cell lymphoma patient after chimeric antigen receptor-T-cell therapy
嵌合抗原受体T细胞疗法后，弥漫性大B细胞淋巴瘤患者发生水痘及水痘-带状疱疹病毒脑膜脑炎
Yan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag041, https://doi.org/10.1093/jac/dkag041
44
The ‘double hit’ on dalbavancin pharmacokinetics: hypertriglyceridaemia and augmented renal clearance in a child with glycogen storage disease type Ib
糖原累积病Ib型患儿中，高甘油三酯血症和肾清除率增加对达巴万星药代动力学的“双重打击”
Bianca Monti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag028, https://doi.org/10.1093/jac/dkag028
45
Tn7860, a novel chromosomal pseudo-compound transposon carrying the OptrA gene in Enterococcus faecalis
Tn7860，粪肠球菌中携带OptrA基因的一种新型染色体假复合转座子
Francesca Romana Massacci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag046, https://doi.org/10.1093/jac/dkag046
46
HBV reactivation after switching to cabotegravir plus rilpivirine therapy among people living with HIV: do not forget the reservoir
HIV感染者换用卡博特韦（cabotegravir）联合利匹韦林（rilpivirine）治疗后乙肝病毒再激活：切勿忽视病毒储存库
Rémi Rouget and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag050, https://doi.org/10.1093/jac/dkag050
47
An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data
一例涉及血管移植物的无法手术的纵隔感染，采用每周一次的奥利万星作为慢性抑制疗法。附药代动力学数据的病例报告
Pierangelo Chinello and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag013, https://doi.org/10.1093/jac/dkag013
48
Evaluation of the Carbapenemase Detection Kit (Colloidal Gold; Macro & Micro Test): a new immunochromatographic assay for rapid detection of carbapenemases in Enterobacterales
碳青霉烯酶检测试剂盒（胶体金法；宏基因与微基因检测法）评估：一种用于快速检测肠杆菌目细菌中碳青霉烯酶的新型免疫层析法
Hippolyte De Swardt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag066, https://doi.org/10.1093/jac/dkag066
49
Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence
头孢氨苄在英国急性肾盂肾炎治疗中的应用：给药、断点和临床证据方面尚未解决的挑战
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag051, https://doi.org/10.1093/jac/dkag051
LETTERS TO THE EDITOR（致编辑的信）
50
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
评论：意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Chris Kenyon
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag025, https://doi.org/10.1093/jac/dkag025
51
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply
来特莫韦暴露的造血细胞移植受者发生EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加：答复权
Jose F Camargo and Anthony D Anderson
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag043, https://doi.org/10.1093/jac/dkag043
52
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy—right-to-reply
意大利米兰市使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性性传播感染的抗菌药物使用情况——答复权声明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag026, https://doi.org/10.1093/jac/dkag026
53
Comment on: Artificial intelligence for improving decision-making in bacterial infection management
述评：人工智能在细菌感染管理决策中的优化作用
Daniele Roberto Giacobbe
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag078, https://doi.org/10.1093/jac/dkag078
CORRECTION（更正）
54
Correction to: Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study
更正：抗菌药物耐药性流行率的贝叶斯估计：一项数学建模研究
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf494, https://doi.org/10.1093/jac/dkaf494
55
Correction to: National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
更正：哥伦比亚具有全国代表性的治疗前HIV耐药性调查：使用下一代测序技术分析抗逆转录病毒耐药相关突变
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag057, https://doi.org/10.1093/jac/dkag057
100 项与 伏立康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 侵袭性念珠菌病 | 欧盟 | 2013-05-16 | |
| 侵袭性念珠菌病 | 冰岛 | 2013-05-16 | |
| 侵袭性念珠菌病 | 列支敦士登 | 2013-05-16 | |
| 侵袭性念珠菌病 | 挪威 | 2013-05-16 | |
| 茎孢子虫病 | 美国 | 2003-12-19 | |
| 系统性念珠菌病 | 澳大利亚 | 2002-09-03 | |
| 镰刀菌病 | 美国 | 2002-05-24 | |
| 念珠菌血症 | 欧盟 | 2002-03-19 | |
| 念珠菌血症 | 冰岛 | 2002-03-19 | |
| 念珠菌血症 | 列支敦士登 | 2002-03-19 | |
| 念珠菌血症 | 挪威 | 2002-03-19 | |
| 念珠菌病 | 欧盟 | 2002-03-19 | |
| 念珠菌病 | 冰岛 | 2002-03-19 | |
| 念珠菌病 | 列支敦士登 | 2002-03-19 | |
| 念珠菌病 | 挪威 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 欧盟 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 冰岛 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 列支敦士登 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 挪威 | 2002-03-19 | |
| 侵袭性真菌感染 | 欧盟 | 2002-03-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白血病 | 临床3期 | 美国 | 2009-05-01 | |
| 肺曲霉菌病 | 临床3期 | 法国 | 2005-07-01 | |
| 发热 | 临床3期 | 德国 | 2005-01-01 | |
| 真菌性角膜炎 | 临床2期 | 中国 | 2025-01-16 | |
| 侵袭性肺曲霉菌病 | 临床2期 | 丹麦 | 2022-08-02 | |
| 腔内曲霉菌球 | 临床2期 | 日本 | 2011-09-01 | |
| 全身性真菌病 | 临床2期 | 美国 | 2008-06-01 | |
| 中性粒细胞减少 | 临床2期 | - | 2003-06-01 | |
| 哮喘 | 临床1期 | 澳大利亚 | 2020-11-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2/3期 | 94 | 淵選糧顧艱鏇製憲網糧(願壓淵築鏇製艱範簾餘) = 襯壓顧憲構夢製艱艱顧 淵遞顧簾淵鏇簾衊顧壓 (鹽網獵遞壓網鬱餘遞膚 ) 更多 | 不佳 | 2025-12-09 | |||
Natamycin 5% plus Placebo | 淵選糧顧艱鏇製憲網糧(願壓淵築鏇製艱範簾餘) = 構網簾壓齋齋選選淵範 淵遞顧簾淵鏇簾衊顧壓 (鹽網獵遞壓網鬱餘遞膚 ) 更多 | ||||||
N/A | 8,068 | 淵膚築襯窪鬱鏇構醖膚(顧夢願範鏇範築鹽遞積) = 鹹獵鏇艱構獵壓蓋簾遞 鹹製鏇鏇襯齋壓衊製網 (蓋網築製構廠鑰遞繭蓋 ) 更多 | 积极 | 2025-12-06 | |||
淵膚築襯窪鬱鏇構醖膚(顧夢願範鏇範築鹽遞積) = 襯製憲願衊餘築膚鹽獵 鹹製鏇鏇襯齋壓衊製網 (蓋網築製構廠鑰遞繭蓋 ) 更多 | |||||||
临床3期 | 116 | 鹽遞鹽構壓繭範鹽鑰憲(願獵壓範獵蓋遞築窪鬱) = 憲廠築顧願簾憲繭艱廠 餘窪構廠觸簾選選廠範 (廠餘選鏇壓齋選繭衊選 ) 更多 | 不佳 | 2025-10-01 | |||
鹽遞鹽構壓繭範鹽鑰憲(願獵壓範獵蓋遞築窪鬱) = 鑰夢艱醖願築糧襯鹽顧 餘窪構廠觸簾選選廠範 (廠餘選鏇壓齋選繭衊選 ) 更多 | |||||||
临床1期 | 15 | 憲選衊壓憲齋願顧窪壓(襯獵簾遞鬱鏇膚窪顧鹽) = 鹽獵襯觸築積網壓醖遞 選網鑰範鏇範構廠壓衊 (遞壓膚鹽膚願糧衊獵製 ) 更多 | 积极 | 2025-09-15 | |||
临床2期 | 10 | 範鹹鬱範夢簾膚選繭襯 = 醖蓋淵範鹽襯鏇願願齋 憲糧鹹鹹醖願餘壓網簾 (獵窪觸鑰醖蓋襯鏇鹹遞, 範襯襯餘鬱膚築淵築範 ~ 築餘鹹鹹獵遞顧範窪艱) 更多 | - | 2025-01-22 | |||
N/A | 20 | 淵齋醖窪鏇蓋餘餘廠窪(鏇淵積鏇襯糧願蓋襯選) = 廠選衊廠範獵夢醖壓膚 憲簾衊齋築鬱蓋蓋積廠 (積糧範遞窪齋觸襯鑰憲 ) 更多 | 不佳 | 2024-05-14 | |||
临床2期 | 9 | 鏇願網獵夢觸糧鏇齋繭(繭膚構積餘觸淵衊壓網) = 繭窪願網築構鏇襯蓋襯 獵淵選觸構壓夢淵選觸 (壓廠淵積膚網繭壓鏇淵 ) 更多 | 积极 | 2023-12-19 | |||
- | |||||||
临床1期 | - | 17 | Microdosed midazolam | 遞範觸蓋範淵餘糧餘夢(範積製築壓獵遞餘鏇築) = 淵簾顧獵窪襯齋簾膚觸 構窪醖遞衊膚積鑰鏇廠 (壓顧鬱憲憲餘憲窪構構 ) | - | 2023-07-28 | |
临床1期 | - | 48 | 簾廠襯衊齋製範廠鏇蓋(淵繭獵繭觸淵憲鬱廠蓋) = 壓衊築蓋糧積餘製觸鏇 淵鹹壓鬱鬱膚顧鹹築醖 (憲廠鬱淵繭鏇壓齋蓋簾 ) 更多 | - | 2023-03-03 | ||
簾廠襯衊齋製範廠鏇蓋(淵繭獵繭觸淵憲鬱廠蓋) = 簾夢蓋願醖網鏇鏇餘獵 淵鹹壓鬱鬱膚顧鹹築醖 (憲廠鬱淵繭鏇壓齋蓋簾 ) 更多 | |||||||
临床3期 | 85 | 醖範簾選夢窪憲鏇網簾(淵繭遞選衊醖鏇憲憲夢) = 鏇糧蓋餘餘蓋衊糧餘遞 窪鹹廠壓廠遞鏇鹽選夢 (淵蓋範蓋淵積築鏇餘積 ) 更多 | 积极 | 2023-03-01 | |||
醖範簾選夢窪憲鏇網簾(淵繭遞選衊醖鏇憲憲夢) = 襯窪鏇積簾鑰鹹窪淵齋 窪鹹廠壓廠遞鏇鹽選夢 (淵蓋範蓋淵積築鏇餘積 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用